Develop novel medicines for immune and inflammatory disorders. Focus on clinical-stage drug development with an emphasis on innovative therapies. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 84% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 11 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $68.7M against $0 in annual sales.
At the current pace of spending, the cash lasts about 1.6 years. After that, the company needs to find new money.
On our five-subject report card, ZURA sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ZURA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (44/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.